Get TestedPost-Exposure Prophylaxis (PEP)
ShareCompartir
Update (May 23, 2018)
Interim Statement Regarding Potential Fetal Harm from Exposure to Dolutegravir – Implications for HIV Post-exposure Prophylaxis (PEP). Please see attached PDF.
PEP is the use of antiretroviral drugs after a single high-risk event to stop HIV seroconversion. PEP must be started as soon as possible to be effective—and always within 72 hours of a possible exposure.
Resources for Consumers
Basic PEP Q&As – learn the basics about PEP and if it’s right for you.
PEP 101 Consumer Info Sheet (English and Spanish)
Resources for Providers
PEP Consultation Service for Clinicians
1-888-448-4911
9 a.m. – 2 a.m. ET
For more information on the services offered through the PEPline, visit the National Clinicians Consultation Center.
Guidelines
- Updated Guidelines for Antiretroviral Postexposure Prophylaxis After Sexual, Injection Drug Use, or Other Nonoccupational Exposure to HIV—United States, 2016
- Updated US Public Health Service Guidelines for the Management of Occupational Exposures to Human Immunodeficiency Virus and Recommendations for Postexposure Prophylaxis
- Updated U.S. Public Health Service Guidelines for the Management of Occupational Exposures to HBV, HCV, and HIV and Recommendations for Postexposure Prophylaxis (Learn more about Learn more about Occupational HIV Transmission and Prevention Among Health Care Workers.)
- Preventing New HIV Infections
- Page last reviewed: May 23, 2018
- Page last updated: May 23, 2018
- Content source: Division of HIV/AIDS Prevention, National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention